How Do Semaglutide and Liraglutide Work at the Molecular Level to Fight Obesity?
Semaglutide and liraglutide combat obesity through multiple molecular mechanisms including appetite suppression, improved insulin secretion, enhanced energy expenditure, and better lipid metabolism.
Quick Facts
What This Study Found
Semaglutide and liraglutide act through five key molecular pathways: appetite regulation via hypothalamic signaling, enhanced insulin secretion, glucose homeostasis, increased energy expenditure, and improved lipid metabolism.
Key Numbers
Obesity is associated with cardiovascular disease, type 2 diabetes, hypertension, and certain cancers. Global prevalence is increasing.
How They Did This
Minireview synthesizing published research on the molecular mechanisms of action of semaglutide and liraglutide in obesity-related metabolic pathways.
Why This Research Matters
Understanding exactly how GLP-1 drugs work at the molecular level helps researchers develop next-generation obesity treatments and helps clinicians predict which patients will benefit most from these therapies.
The Bigger Picture
As GLP-1 receptor agonists become the most impactful obesity medications in decades, this mechanistic understanding provides the foundation for developing even more targeted and effective treatments in the expanding weight management field.
What This Study Doesn't Tell Us
Minireview format without systematic search methodology; focuses primarily on semaglutide and liraglutide without comprehensive comparison to newer GLP-1 agents; does not cover emerging combination therapies like tirzepatide.
Questions This Raises
- ?Which of the five molecular pathways contributes most to the weight loss effects of these drugs?
- ?How do individual genetic variations in GLP-1 receptor expression affect treatment response?
- ?Can these molecular insights guide development of oral GLP-1 formulations with equivalent efficacy?
Trust & Context
- Key Stat:
- 5 pathways molecular mechanisms through which GLP-1 RAs combat obesity
- Evidence Grade:
- Strong as a review, synthesizing well-established molecular biology research and clinical trial data on two FDA-approved medications.
- Study Age:
- Published in 2024, providing a current overview of established and emerging GLP-1 receptor agonist mechanisms.
- Original Title:
- Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.
- Published In:
- Frontiers in nutrition, 11, 1398059 (2024)
- Authors:
- Tamayo-Trujillo, Rafael, Ruiz-Pozo, Viviana A, Cadena-Ullauri, Santiago, Guevara-Ramírez, Patricia, Paz-Cruz, Elius, Zambrano-Villacres, Raynier, Simancas-Racines, Daniel, Zambrano, Ana Karina
- Database ID:
- RPEP-09364
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do semaglutide and liraglutide actually cause weight loss?
They activate GLP-1 receptors throughout your body, which suppresses appetite by signaling fullness to your brain, boosts insulin to control blood sugar, increases how much energy your body burns, and improves how your body processes fats.
What's the difference between how semaglutide and liraglutide work?
They both target the same GLP-1 receptor and share the same core mechanisms. The main difference is structural — semaglutide has modifications that make it last longer in the body, allowing once-weekly dosing versus liraglutide's daily injection.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09364APA
Tamayo-Trujillo, Rafael; Ruiz-Pozo, Viviana A; Cadena-Ullauri, Santiago; Guevara-Ramírez, Patricia; Paz-Cruz, Elius; Zambrano-Villacres, Raynier; Simancas-Racines, Daniel; Zambrano, Ana Karina. (2024). Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.. Frontiers in nutrition, 11, 1398059. https://doi.org/10.3389/fnut.2024.1398059
MLA
Tamayo-Trujillo, Rafael, et al. "Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.." Frontiers in nutrition, 2024. https://doi.org/10.3389/fnut.2024.1398059
RethinkPeptides
RethinkPeptides Research Database. "Molecular mechanisms of semaglutide and liraglutide as a the..." RPEP-09364. Retrieved from https://rethinkpeptides.com/research/tamayo-trujillo-2024-molecular-mechanisms-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.